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INTRODUCTION: Ameloblastoma is a rare, 
benign oral tumour. Tumours develop within the 
jaw bone and are highly destructive and invasive, 
with cells migrating into the jaw and surrounding 
soft tissue. This is a little-understood disease which 
if left untreated causes dramatic bone destruction 
and maxillofacial disfigurement. Current treatment 
is radical surgery, often resulting in extensive loss 
of function and tissue. An ameloblastoma-derived 
cell line, AM-1, has been established [1]. Cells 
were isolated from a human tumour and 
immortalised by the addition of HPV-16 DNA. 
This study aims to (i) make a 3D in vitro 
ameloblastoma disease model, using plastic-
compressed collagen gel [2] seeded with AM-1 
cells, and (ii) use this bone construct to 
characterise tissue remodelling, cell growth and 
invasiveness.  
 
METHODS: Collagen type I, isolated from rat 
tails (First Link UK), was used to make hydrated 
gels suitable for seeding cells. Ameloblastoma 
AM-1 cells [1] cells were added to the gel.  Plastic 
compression was then used to expel the water 
content, rapidly increasing the gel’s mechanical 
strength without compromising cell viability [2]. 
Compressed gels were rolled into spirals to provide 
easy handling and provide a biomimetic 3D 
environment to observe cell viability and 
behaviour. Gels were incubated at 37°C with 5% 
CO2, in keratinocyte-serum-free medium (Gibco) 
supplemented with fibroblast growth factor 
(Peprotech UK). 
 
Constructs were cultured for up to 4 weeks to 
observe the extent of collagen remodelling and 
differences in cell viability at different time points. 
Immunohistochemistry was performed to visualise 
the expression of bone- and cancer-associated 
proteins (Abcam, Vector Labs). The alamarBlue 
cell growth assay (AbD Serotec) and live/dead 
fluorescence assay (Invitrogen) were carried out to 
assess AM-1 cell growth and viability in bone 
construct culture. IHC was carried out at the Royal 
London Hospital Pathology laboratory. 
 
RESULTS: AM-1 cells are viable in this bone 
construct, demonstrated by the alamarBlue growth 
curve and live/dead fluorescence assay (see Fig. 1). 
Expression of epithelial marker vimentin, early 
bone marker alkaline phosphatase and matrix 
metalloproteinase-2 (MMP-2) was detected in AM-
1 seeded bone constructs (see Fig. 2).  
Fig. 1: Live/dead fluorescence assay; green = live, 
red = dead. AM-1 cells are viable in the construct. 
Fig. 2: IHC shows vimentin expression (brown) in 
AM-1 seeded bone construct. 
DISCUSSION & CONCLUSIONS: Compressed 
collagen gel is an appropriate tissue model for 
research into ameloblastoma, as it is a native 
material which provides good mimicry of bone 
tissue; its construction is ultrarapid and 
reproducible; and it allows cell growth and 
migration. AM-1 cells proliferate in the bone 
construct, as shown by the viability assays. 
Expression of vimentin, alkaline phosphatase and 
MMP-2 show that this disease model retains in 
vivo behaviours of ameloblastoma, therefore we 
have made progress towards a representative 
disease model. 
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